creat bluematrix
neutral takeaway guggenheim
path accel approv
messag host firesid chat presid ceo mark enyedi
guggenheim healthcar talk idea forum oncolog day held today new
york citi takeaway remain confid mirvetuximab potenti
acceler path market ovarian cancer base new soraya trial
plan ensur effici concurr enrol soraya
confirmatori ph mirasol trial similar patient subset potenti compendia
list mirv combin could help expand market opportun longer term
updat data could set stage registration-en studi
bpdcn aml respect
rate neutral lead product candid mirvetuximab soravtansin
folate-receptor alpha fr -target evalu singl agent
combin patient ovarian cancer phase forward studi
near miss primari endpoint subgroup analysi fr high patient show consist
signal efficaci link base result think like imgn
plan second pivot trial soraya succeed said expect stock
rangebound studi fulli enrol like beyond mirvetuximab
develop second product candid hematolog
oncolog indic includ bpdcn aml partner option licens
updat phase result like late could potenti provid
addit insight potenti opportun hematolog cancer
current model
new registration-en soraya trial initi recal
base recent fda guidanc new single-arm studi could potenti support
acceler approv mirvetuximab soravtansin platinum-resist ovarian cancer
proc base guidanc compani initi soraya pivot single-arm
trial evalu mirvetuximab monotherapi women folat receptor alpha fr
high platinum-resist ovarian cancer previous treat avastin
bevacizumab trial enrol patient orr dor endpoint
potenti complet per file potenti posit
base calcul think mirvetuximab need demonstr least
orr lower bound confid interv clear orr histor
benchmark singl agent chemotherapi aurelia corail context
orr report similar patient per post-hoc analysi think
like trial succe
previous announc random mirasol phase trial convert
confirmatori phase slightli broader set note previous base
previou discuss fda initi random phase
mirasol trial recal trial serv confirmatori studi random
patient receiv either mirvetuximab investig choic single-
agent chemotherapi weekli paclitaxel pegyl liposom doxorubicin topotecan
elig criteria slightli broader soraya prior avastin treatment requir
includ patient platinum-resist ovarian cancer whose tumor express high
level fr use score method treat
three prior regimen primari endpoint studi progress free surviv
secondari endpoint includ overal respons rate overal surviv patient-report
outcom state expect mirasol trial complet bla
submiss like ask manag note strateg clinic
oper plan place ensur concurr enrol similar patient
page analyst certif import disclosur
clinic trial effici specif trial site within geograph territori avastin
use earlier treatment preferenti enrol soraya first wherea
other primarili enrol mirasol management highlight site
global gain experi mirvetuximab confid rapid
patient enrol trial
combin potenti maxim mirvetuximabc commerci opportun
continu run multi-cohort phase ii forward ii studi evalu
mirvetuximab combin number drug approv ovarian cancer
includ avastin keytruda platinum-resist ovarian cancer triplet
regimen avastin carboplatin platinum-sensit ovarian cancer base result
gener far plan go forward addit cohort forward ii
evalu mirvetuximab avastin ovarian cancer patient regardless platinum
sensit fulli enrol top-lin result expect annual meet per
guidanc separ ist commenc compar mirvetuximab carboplatin
vs carboplatin alon platinum-sensit patient trial success could
potenti support compendia list
data sever expans cohort present recal
develop sever hematolog cancer
includ aml bpdcn recommend phase dose identifi
initi expans cohort evalu monotherapi
front-lin mrd aml patient doublet combin regimen azacitidin vidaza
venetoclax venclexta r/r aml triplet combin regimen
azacitidin venetoclax front-lin unfit aml patient initi data
expans cohort present per could potenti trigger late
stage trial support
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst whose name appear report receiv compens base upon variou factor includ qualiti research
investor client feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic
inc next month
guggenheim secur llc make market secur deriv inc
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori inc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
